Biopharma News

Apr 21, 2017
Valeant said the IL-17 inhibitor will be listed at $3500 per month and is expected to be available for sale during the second half of 2017.
Apr 21, 2017
Amgen asked a judge to issue a judgment of infringement involving Sanofi/Regeneron’s drug Dupixent and its use of a mechanism described in Amgen’s ‘487 patent.
Apr 21, 2017
The agency approved Renflexis, a biosimilar to Janssen’s blockbuster rheumatoid arthritis treatment.
Apr 20, 2017
The company said it would not renew marketing authorization of Glybera, the first gene-therapy approved in the EU.
Apr 18, 2017
By BioPharm International Editors
Cobra will increase capacity in response to customer demand for DNA and viral vector production.
Apr 17, 2017
By BioPharm International Editors
The two companies will develop translational biomarkers for fibrotic diseases, including non-alcoholic steatohepatitis (NASH).
Apr 13, 2017
By BioPharm International Editors
BMS is licensing two investigational compounds in separate deals with Roche and Biogen for a total of $470 million in upfront payments.
Apr 07, 2017
By BioPharm International Editors
Janssen will have access to PeptiDream’s proprietary Peptide Discovery Platform System technology, which will be used to identify peptides against multiple metabolic and cardiovascular targets.
Apr 07, 2017
By BioPharm International Editors
The companies will work to co-develop FIN-524, a live biotherapeutic product composed of cultured bacteria strains.
Mar 30, 2017
The company received priority review for its investigational CAR-T therapy to treat leukemia.
native1_300x100
lorem ipsum